Physician profile
Michael Tolwin
NPI 1497797427
$11,593.21
in general payments reported to CMS, 2019-2025
19 companies · $916 in 2025
The $916 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,761 · 2020: $2,014 · 2021: $1,462 · 2022: $1,003 · 2023: $1,848 · 2024: $1,589 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,699.43 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $1,533.65 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $1,364.18 | 2019-2022 | |
| Alkermes, INC. | $1,354.24 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,342.08 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,093.08 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $754.69 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $627.42 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Nuedexta |
| Neurocrine Biosciences, INC. | $398.68 | 2019-2025 | Ingrezza |
| Allergan, INC. | $388.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $291.44 | 2019-2020 | |
| Indivior INC. | $265.60 | 2020-2023 | Perseris |
| Harmony Biosciences LLC | $192.86 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $86.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.75 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $63.15 | 2019-2020 | |
| Almatica Pharma LLC | $31.02 | 2023 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $20.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tolwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.